Cerus Corporation
$ 3.12
-0.95%
10 Jul - close price
- Market Cap 625,151,000 USD
- Current Price $ 3.12
- High / Low $ 3.17 / 3.02
- Stock P/E N/A
- Book Value 0.34
- EPS -0.05
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.15 %
- 52 Week High 3.47
- 52 Week Low 1.15
About
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Analyst Target Price
$4.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-02 | 2025-11-06 | 2025-08-05 | 2025-05-01 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-03-05 | 2023-11-02 | 2023-08-02 |
| Reported EPS | -0.01 | -0.01 | -0.0001 | -0.03 | -0.04 | -0.01 | -0.02 | -0.03 | -0.05 | -0.01 | -0.03 | -0.06 |
| Estimated EPS | -0.04 | -0.0075 | -0.02 | -0.02 | -0.05 | -0.01 | -0.03 | -0.04 | -0.04 | -0.02 | -0.05 | -0.06 |
| Surprise | 0.03 | -0.0025 | 0.0199 | -0.01 | 0.01 | 0 | 0.01 | 0.01 | -0.01 | 0.01 | 0.02 | 0 |
| Surprise Percentage | 75% | -33.3333% | 99.5% | -50% | 20% | 0% | 33.3333% | 25% | -25% | 50% | 40% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERS
2026-07-11 01:09:43
Cerus Corporation has updated the employment terms for William Greenman following his transition to Executive Chairman, effective July 1, 2026. He will serve until May 31, 2027, with a reduced time commitment, and will receive an annual base salary of $500,000, plus an 80% target annual cash bonus for 2026 only. The company will also cover COBRA health insurance premiums if his role change qualifies.
2026-07-09 13:46:54
Cerus Corp operates in the demanding healthcare environment of blood safety systems, focusing on pathogen reduction technology. The company's success relies on the adoption of its systems by blood centers and hospitals, which face regulatory scrutiny, budget constraints, and evolving safety standards. Cerus Corp's strategy involves demonstrating both the clinical effectiveness and economic value of its pathogen reduction systems to ensure long-term integration into transfusion practices.
2026-07-08 14:09:32
Cerus Corp (CERS) focuses on developing medical technologies to enhance blood transfusion safety, particularly through its pathogen reduction systems for platelets and plasma. The company, listed on Nasdaq, aims to reduce the risk of infection from transfused blood components for hospitals and blood centers globally. Its business model, which combines capital equipment sales with recurring consumable revenues, supports long-term growth as more healthcare systems adopt its INTERCEPT Blood System.
2026-07-07 16:39:46
Cerus Corp specializes in pathogen reduction systems for blood components, enhancing transfusion safety globally. The company's business model focuses on expanding its technology and partnerships with healthcare providers and blood centers. Investors are keenly watching the long-term adoption of Cerus technology, its revenue growth, and market expansion as key indicators for future performance.
2026-07-06 00:39:46
This article provides comprehensive financial data and market performance metrics for Cerus Corp (CERS), highlighting its latest stock price, financial ratios, sales figures, and insider transaction details. It offers a snapshot of the company's current market position, including volatility, relative volume, and analyst recommendations. The data indicates various performance metrics over different periods, offering insights into its stock trend and financial health.
2026-07-03 23:40:36
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), sold 24,329 shares of common stock totaling $71,597 on June 30, 2026. These sales were not discretionary but rather to cover tax withholding obligations and brokerage fees related to restricted stock unit vesting. Following these transactions, Jensen directly holds 966,657 shares of CERUS CORP.
